MedPath

Efficacy of Gamification in Enhancing User Engagement

Not Applicable
Completed
Conditions
Dementia
Gamification
Alzheimer Disease
Assistive Technology
Interventions
Device: The MapHabit system
Registration Number
NCT05422339
Lead Sponsor
MapHabit, Inc.
Brief Summary

As part of Phase II of the NIH SBIR grant, the study will conduct a randomized controlled clinical trial in which the MapHabit system's gamification is investigated to determine whether the assistive technology facilitates user engagement and retention. Additionally, the study will examine if the gamified software improves the quality of life of persons with dementia and reduce the burden of the respective care partners. Participants will be individuals with Alzheimer's disease or related dementias in mild to moderate stage of cognitive impairment, in tandem with their respective care partner (i.e., primary familial caregiver). The study will be a randomized controlled clinical trial, in which three conditions will be investigated: 1) experimental condition in which MHS+G is implemented into the daily care received by participants 2) control condition in which the MHS alone is incorporated into the participant's daily care 3) exploratory condition where virtual reality gamification is incorporated into the MHS+G experience. The sample size will be a total of 40 individual-caregiver dyads, 20 in each condition-5 of the 20 subjects in the experimental condition will be included in exploratory condition. The study duration will be a 6-month intervention.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
32
Inclusion Criteria
  • Individual diagnosed with Alzheimer's disease or other related dementia (ADRD) in their mild to moderate stage of impairment
  • Participating caregiver of individual with dementia must be the primary caregiver
  • Proficient in English
Exclusion Criteria
  • Individual not diagnosed with ADRD
  • Participating caregiver of individual with dementia is NOT the primary caregiver
  • Not proficient in English

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Non-gamified InterventionThe MapHabit systemThis control condition acted as the active comparator to the experimental condition. The same assistive technology, the MapHabit system, will be given to a separate group of participants. The difference here will be that the software will be a version that does not include gamification features.
Exploratory InterventionThe MapHabit systemThe exploratory condition will be given the same MHS version as the active comparator (control condition). However, for this group, participants will also engage in virtual reality games throughout the duration of the study. These virtual reality games are integrated with the MHS and includes cognitive games revolving around mental acuity, motor skills, etc.
Gamified InterventionThe MapHabit systemThis condition will involve the implementation of an assistive technology software (named the MapHabit system) with added gamification features into the daily care of individuals with mild to moderate stage of dementia. The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The application will be made available to families through compatible tablets.
Primary Outcome Measures
NameTimeMethod
Change in User Interaction and Engagement from baseline at 6 monthsPre-Post: The analytics will be administered at the beginning and end of the study's duration (i.e., assessed at baseline when participant starts to use the app and then again at 6 months study completion)

Our internal analytics of the software can assess the user's interactions with the application, including screen time, number of taps on the screen, number of completed activities, etc. By combining these data points, we can determine the average engagement for each participant and compare them between groups.

Change in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) from baseline at 6 monthsPre-Post: The assessment was administered at the beginning and end of the study's duration (6-month study).

Assesses an individual with dementia's ability to carry out activities of daily living. The total score ranges from 0-53, with a higher score representing better performance in completing activities of daily living by the individual with dementia.

Quality of Life - 18 (QoL-18)The instrument will be administered to the participants after the completion of the study duration (6-month study

18-item quality-of-life questionnaire (QoL-18) evaluated a range of participants' behaviors, including mood, engagement, and memory at the end of the study compared to before the use of the MHS. The instrument is scored on a Likert Scale, ranging from 1-5. A higher number indicates better outcome.

Change in Margaret Blenkner Research Center (MBRC) Caregiver Strain instrument from baseline at 6 monthsPre-Post: The assessment will be administered at the beginning and end of the study's duration (6-month study).

14-item questionnaire assessing the various stresses caregivers experienced related to caring for an individual with cognitive impairment. The total score ranges from 0-42, with a higher score reflecting higher stress and burden on the caregiver.

Secondary Outcome Measures
NameTimeMethod
2-item Satisfaction Scale (SS-2)The instrument was administered to the participants after the completion of the study duration ((i.e., assessed at 6 months)

Quantifies caregivers' endorsements to two survey questions: How satisfied were they with the MHS? Would they recommend MHS to others? Both questions are scored on a 10-point scale, with a higher value reflecting a better outcome/experience.

Trial Locations

Locations (1)

MapHabit

🇺🇸

Atlanta, Georgia, United States

© Copyright 2025. All Rights Reserved by MedPath